The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension

Journal of the American College of Cardiology

Volumn 60, Issue 13, 2012, Pages 1202-1203

  Rich, Stuart ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

6 minute walk test; clinical trials; pulmonary hypertension

Indexed keywords

PROSTACYCLIN;

6 MINUTE WALK TEST; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; DRUG SAFETY; EXERCISE TOLERANCE; HEART MUSCLE BLOOD FLOW; HUMAN; LUNG HEMODYNAMICS; NOTE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; WALKING;

EID: 84866421130     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.03.080     Document Type: Editorial

References (14)

1. Mark Twain http://www.brainyquote.com/quotes/quotes/m/marktwain100019. html Accessed August 2012
2. L. Bianchi, A. Angelini, F. Lacquaniti Individual characteristics of human walking mechanics Pflügers Arch 436 1998 343 356
3. ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
4. A.L. Clark, P.A. Poole-Wilson, A.J. Coats Exercise limitation in chronic heart failure: central role of the periphery J Am Coll Cardiol 28 1996 1092 1102
5. R.J. Barst, L.F. Rubin, W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301
6. R.J. Gibbons, G.J. Balady, J.W. Beasley ACC/AHA guidelines for exercise testing A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing) J Am Coll Cardiol 30 1997 260 311
7. R.S. Engelmeier, J.B. O'Connell, R. Walsh, N. Rad, P.J. Scanlon, R.M. Gunnar Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial Circulation 72 1985 536 546
8. R.J.A. Butland, J. Pang, E.R. Gross, A.A. Woodcock, D.M. Geddes Two-, six-, and 12-minute walking tests in respiratory disease Br Med J (Clin Res Ed) 284 1982 1607 1608
9. A. Macchia, R. Marchioli, G. Tognoni Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed Am Heart J 159 2009 245 257
10. G. Savarese, S. Paolillo, P. Constanzo Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials J Am Coll Cardiol 60 2012 1199 1201
11. D.A. Redelmeier, A.M. Bayoumi, R.S. Goldstein, G.H. Guyatt Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients Am J Respir Crit Care Med 155 1997 1278 1282
12. S. Rich The effects of vasodilators for pulmonary hypertension: pulmonary vascular or peripheral vascular? Circ Heart Fail 2 2009 145 150
13. R.O.D. Achcar, G.L. Yung, H. Saffer, C.D. Cool, N.F. Voelkel, E.S. Yi Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension Eur J Med Res 11 2006 203 207
14. S. Rich, J. Pogoriler, A. Husain, P.T. Toth, M. Gomberg-Maitland, S.A. Archer Long term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension Chest 138 2010 1234 1239